$541 Million is the total value of Broadfin Capital, LLC's 44 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | New | SPDR S&P 500 ETF TRput | $130,579,000 | – | 440,000 | +100.0% | 24.14% | – |
| XBI | New | SPDR SERIES TRUSTput | $53,375,000 | – | 700,000 | +100.0% | 9.87% | – |
| XENT | New | INTERSECT ENT INC | $13,253,000 | – | 779,134 | +100.0% | 2.45% | – |
| ABBV | New | ABBVIE INC | $11,699,000 | – | 154,500 | +100.0% | 2.16% | – |
| PGNX | New | PROGENICS PHARMACEUTICALS IN | $8,007,000 | – | 1,583,925 | +100.0% | 1.48% | – |
| XCUR | New | EXICURE INC | $5,849,000 | – | 2,311,906 | +100.0% | 1.08% | – |
| ALKS | New | ALKERMES PLC | $4,858,000 | – | 249,000 | +100.0% | 0.90% | – |
| XGN | New | EXAGEN INC | $4,822,000 | – | 311,284 | +100.0% | 0.89% | – |
| ICUI | New | ICU MED INC | $4,788,000 | – | 30,000 | +100.0% | 0.88% | – |
| DERM | New | DERMIRA INC | $3,704,000 | – | 579,600 | +100.0% | 0.68% | – |
| GWPH | New | GW PHARMACEUTICALS PLCads | $3,451,000 | – | 30,000 | +100.0% | 0.64% | – |
| ACRS | New | ACLARIS THERAPEUTICS INC | $1,750,000 | – | 1,620,000 | +100.0% | 0.32% | – |
| AMAG | New | AMAG PHARMACEUTICALS INC | $1,155,000 | – | 100,000 | +100.0% | 0.21% | – |
| PTN | New | PALATIN TECHNOLOGIES INC | $952,000 | – | 1,047,310 | +100.0% | 0.18% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Broadfin Healthcare Master Fund Ltd #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIODELIVERY SCIENCES INTL IN | 27 | Q4 2019 | 4.8% |
| HERON THERAPEUTICS INC | 24 | Q4 2019 | 9.0% |
| LA JOLLA PHARMACEUTICAL CO | 24 | Q4 2019 | 7.7% |
| RECRO PHARMA INC | 24 | Q4 2019 | 4.1% |
| ANTARES PHARMA INC | 24 | Q3 2019 | 3.4% |
| RETROPHIN INC | 23 | Q3 2019 | 7.0% |
| ARATANA THERAPEUTICS INC | 22 | Q2 2019 | 8.1% |
| MIRATI THERAPEUTICS INC | 22 | Q1 2019 | 7.9% |
| CATALYST PHARM PARTNERS INC | 22 | Q3 2019 | 6.2% |
| ANGIODYNAMICS INC | 21 | Q3 2018 | 6.6% |
View Broadfin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.Sold out | January 04, 2021 | 0 | 0.0% |
| LA JOLLA PHARMACEUTICAL COSold out | January 04, 2021 | 0 | 0.0% |
| STRATA Skin Sciences, Inc. | June 23, 2020 | 1,529,392 | 4.5% |
| Teligent, Inc.Sold out | February 25, 2020 | 0 | 0.0% |
| Neos Therapeutics, Inc.Sold out | February 14, 2020 | 0 | 0.0% |
| Aclaris Therapeutics, Inc. | February 13, 2020 | 1,888,039 | 4.6% |
| Adamas Pharmaceuticals IncSold out | February 13, 2020 | 0 | 0.0% |
| ADMA BIOLOGICS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
| AVADEL PHARMACEUTICALS PLC | February 13, 2020 | 1,029,012 | 2.8% |
| CATALYST PHARMACEUTICALS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
View Broadfin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-03-22 |
| 4 | 2022-02-15 |
| 4 | 2022-01-31 |
| 4 | 2021-11-22 |
| 4 | 2021-11-15 |
| 4 | 2021-11-09 |
| 4 | 2021-08-10 |
| 4 | 2021-05-13 |
| SC 13G/A | 2021-01-04 |
| SC 13G/A | 2021-01-04 |
View Broadfin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.